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Dopamine is a neurotransmitter of great physiological relevance. Disorders in dopaminergic signal 
transduction are associated with psychiatric and neurological pathologies such as parkinson’s 
disease, schizophrenia and substance abuse. therefore, a detailed understanding of dopaminergic 
neurotransmission may provide access to novel therapeutic strategies for the treatment of these 
diseases. caged compounds with photoremovable groups represent molecular tools to investigate a 
biological target with high spatiotemporal resolution. Based on the crystal structure of the D3 receptor 
in complex with eticlopride, we have developed caged D2/D3 receptor ligands by rational design. We 
initially found that eticlopride, a widely used D2/D3 receptor antagonist, was photolabile and therefore 
is not suitable for caging. Subtle structural modification of the pharmacophore led us to the photostable 
antagonist dechloroeticlopride, which was chemically transformed into caged ligands. Among those, 
the 2-nitrobenzyl derivative 4 (MG307) showed excellent photochemical stability, pharmacological 
behavior and decaging properties when interacting with dopamine receptor-expressing cells.
Photopharmacology substantially contributes to our understanding of receptor function, potentially paving the 
way for new therapeutics1. Hence, photoswitchable small molecules and neuropeptides have facilitated optical 
control of GPCR function2. Moreover, photoactivable agonists and antagonists (caged ligands) have been devel-
oped3. The rapid spatiotemporal control of such ligands upon photo-uncaging provides valuable insights into 
kinetics of association, dissociation as well as receptor-induced signalling. In vivo photopharmacology has been 
a significant challenge, because delivery of UV light to deep tissue infusion is technically challenging. However, 
new wireless devices being able to co-deliver light and drug or prodrug simultaneously may be a major break-
through4. Caged compounds consist of a biologically active molecule masked by a photolabile protective group, 
to prevent target binding and thus attenuate biological activity. Upon suitable illumination, photolytic cleavage 
of the cage leads to rapid release of the active molecule towards cellular targets via concentration jumps, ideally 
within the time span of a light pulse5,6. Most prominent photosensitive masking groups are nitrobenzyl deriva-
tives. These well-established cages have previously been introduced to a wide range of functionalities including 
ions7,8, phosphates9, phenols10–13, amines13 and carboxylic acids14. Photolytic cleavage of nitrobenzyl-type cages 
proceeds via a radical mechanism and is triggered by UV illumination with excitatory wavelengths ranging from 
300 to 400 nm15. Simple structural modifications involving formal introduction of two methoxy substituents 
allowed a cleavage with light of longer wavelengths13,15,16.
The neurotransmitter dopamine is critically involved in the regulation of movement, fine-motor control, 
emotions and behavior. Its physiological effects are mediated via five G protein-coupled receptors (GPCRs), the 
dopamine receptors D1 – D5. Irregularities in the dopaminergic system are related to psychiatric and neurolog-
ical pathologies including Parkinson’s disease, schizophrenia and substance abuse17,18. Whereas dopaminergic 
agonists are successfully used for the treatment Parkinson’s disease, D2/D3 receptor antagonists reduce positive 
symptoms of schizophrenia and are of interest to treat addiction19,20. Hence, the discovery of selective ligands for 
D2/D3 receptors is still an active field of drug research21–29.
Caged dopamine derivatives have been employed for kinetic experiments on neurotransmitter release and 
clearance30–34, for electrophysiological experiments34 and for the mapping of dopamine receptors in brain slice 
preparations31. However, the repertoire is limited to caged dopamine. In order to expand the range of such studies 
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to selective D2/D3 receptor antagonists, we have developed caged eticlopride analogs35,36. Here we describe the 
development of the caged dopamine receptor antagonist 4 (MG307) showing excellent photochemical stability, 
pharmacological behavior and decaging properties, when interacting with D2 receptor-expressing cells.
Results
compound design and synthesis. Efficient caging primarily requires the identification of an appropriate 
position for the introduction of a cage. For the design of a caged antagonist, the crystal structure of the D3R in 
complex with the pharmacological agent eticlopride served as a starting point37. Because the binding pockets 
for D2R and D3R are very similar and eticlopride is known as a high affinity antagonist for both subtypes, our 
approach was expected to guide us to caged ligands suitable for both subtypes. The structure reveals that the 
pyrrolidine ring is oriented towards the extracellular space, whereas the aromatic residue of the pharmacophore 
is surrounded by the orthosteric D3R binding pocket (Fig. 1). In consequence, the introduction of a sterically 
demanding substituent into the phenyl moiety should induce repulsive interactions and thus substantial loss of 
binding affinity. Therefore, the phenol functionality appeared attractive for the introduction of a photoremovable 
cage.
Expecting a very similar binding pose for eticlopride and its more stable analog dechloroeticlopride38 at D3 
and the homologous D2 receptor, we aimed to synthesize the 2-nitrobenzyl (NB) and dimethoxynitrobenzyl 
(DMNB) protected derivatives 1, 2, 4 (MG307) and 5 (Fig. 2) and investigate those for their biological proper-
ties. The experiments were planned to be conducted before and after photoactivation, in comparison to eticlo-
pride and dechloroeticlopride. The unsubstituted benzyl derivatives 3 and 6 were prepared as photostable control 
agents. Chemical synthesis of the test compounds 1, 2, 4 (MG307), 5 and 6 was performed by O-alkylation of 
eticlopride and dechloroeticlopride with 2-nitrobenzyl bromide, 4,5-dimethoxy-2-nitrobenzyl bromide or benzyl 
bromide in presence of potassium carbonate, when acetone was used as a solvent. For the preparation of the con-
trol agents 3, the introduction of the benzyl group was conducted before the final amide coupling. Details on the 
synthesis and analytical data of the newly prepared compounds are provided in the Supplementary Information.
compound characterization and photochemistry. Initially, the caged compounds 1 and 2 as well as 
eticlopride were examined in UV/Vis absorption measurements and illumination experiments for optical and 
photochemical characterization. All measurements were performed in aqueous buffer solution. Compound sta-
bility and photolysis was monitored by HPLC. UV/Vis absorption spectra (λ = 210–400 nm) revealed that the 
DMNB derivative 2 shows two overlapping local maxima at λ = 285 nm and λ = 345 nm, whereas the NB analog 
1 exhibits a local maximum at λ = 265 nm (Fig. 3A). Interestingly, eticlopride shows a local absorption maxi-
mum at λ = 325 nm and weaker but significant absorption up to approximately 360 nm. Excitation of NB- and 
DMNB-type cages to trigger photolysis is usually performed with light of 300–400 nm. This absorption profile 
may limit the wavelength range for cage photolysis, as simultaneous excitation of the core pharmacophore may 
trigger photolytic degradation of the desired product. We performed photolysis experiments using a near UV 
light-emitting diode (LED) light source with a peak wavelength of λp = 365 nm and a spectrum half width of 
Δλ = 9 nm. In fact, NB-caged compound 1 showed complete photolysis after seconds of irradiation, although its 
molecular absorption at the irradiated wavelength of 365 nm is low (Supplementary Fig. S1A). Rapid photolytic 
degradation was also observed for the DMNB-caged compound 2 (Supplementary Fig. S1B). Interestingly, HPLC 
analysis showed that irradiation with λp = 365 nm produced only small amounts of eticlopride, but triggered the 
formation of complex mixtures of decomposition products (Supplementary Fig. S1). One of the composition 
products was found to be identical with dechloroeticlopride, a compound that may have been produced by radical 
or anionic dechlorination upon deprotection. Employing HPLC and LCMS, we found that compounds 1 and 2 
were not fully stable and slowly decomposed to liberate eticlopride even in the absence of light, drastically limit-
ing their applicability within a biological system.
Figure 1. Ligand design. Binding mode of eticlopride in the D3R binding pocket as revealed by X-ray 
crystallography37 (a) and caging strategy based thereon (b).
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Photochemical characterization of dechloroeticlopride indicated that the compound may be more photosta-
ble towards light of λ = 365 nm, when a local UV absorption maximum was identified at λ = 315 nm with minor 
absorption at wavelengths higher than 350 nm (Fig. 3B). According to HPLC analysis, no significant decompo-
sition was observed upon illumination with light of λp = 365 nm in aqueous buffer. We found that the absorp-
tion profiles of caged compounds 4 (MG307) and 5 are almost identical with the eticlopride derivatives 1 and 2 
(Fig. 3A,B). Local absorption maxima were observed at λ = 275 nm for NB-caged compound 4 (MG307) and at 
λ = 285 nm and λ = 354 nm for DMNB-caged compound 5. Most importantly, clean photolysis was observed for 
the caged compounds 4 (MG307) and 5 (Fig. 3C,D). Hence, upon irradiation with λp = 365 nm dechloroeticlo-
pride was liberated in high yield from both precursors. No unspecific degradation of the pharmacophore was 
observed, resulting in constant concentration of the desired product. We determined quantum yields of ϕ = 0.5% 
for uncaging of 4 (MG307) and ϕ = 2.1% for 5, respectively, for the photolytic liberation of dechloroeticlopride. 
The caged dechloroeticlopride derivatives 4 (MG307) and 5 were stable under storage conditions and in solution 
for at least two days, when handled in the dark. The exposure to ambient light for longer time led to partial pho-
tolytic degradation. After incubation in aqueous buffer at ambient light for 1 h, we detected remaining 51% and 
62% of the initial concentrations of 4 (MG307) and 5, respectively.
Receptor binding and functional studies. We have examined all caged test compounds in radioligand 
binding assays, to determine their affinity towards the dopamine receptor subtypes D2S, D2L, D3 and D4 in com-
parison to the uncaged analogs. For the uncaged compounds we additionally measured binding affinities to the 
dopamine receptor subtypes D1, D5, the serotonin receptor subtypes 5-HT1A and 5-HT2A as well as the adrenergic 
receptors α1A, α2A, and β2. Competition binding experiments were performed with membranes from CHO cells 
stably expressing the receptors of the D2 family (D2S, D2L, D3, and D4) and the radioligand [3H]spiperone or from 
HEK293T cells transiently transfected with D1, D5, 5-HT1A, 5-HT2A, α1A, α2A, and β2 and the radioligands [3H]
SCH23390 (D1, D5), [3H]WAY600135 (5-HT1A), [3H]ketanserin (5-HT2A), [3H]prazosin (α1A), [3H]RX821002 
(α2A), and [3H]CGP12177 (β2). To monitor functional effects, the caged compounds 4 (MG307), 5, and 6 and 
dechloroeticlopride, were examined in inositol aphosphate (IP) accumulation assay at D2SR co-expressed with 
the hybrid Gαqi-protein (Gαq protein with the last five amino acids at the C-terminus replaced by the corre-
sponding sequence of Gαi). We have recently established this assay for the examination of photoswitchable 
dopaminergic compounds39. After initial characterization of the compounds, the effect of uncaging by illumi-
nation at λ = 365 nm on IP accumulation was studied. Hence, photolytic release of dechloroeticlopride was 
examined antagonizing the activating properties of the D2-like receptor agonist quinpirole. In fact, the results 
of our radioligand binding studies demonstrated that the caging strategy was working for the benzamide-type 
pharmacophores (Supplementary Table 1, 2). Whereas eticlopride showed excellent binding affinity at D2 and 
D3 receptors with subnanomolar Ki values (0.21–0.28 nM), the benzylated photostable control agent 3 exhibited 
very low affinity towards all dopamine receptor subtypes with Ki values in the micromolar concentration range 
(Ki = 4800–22000 nM). As anticipated from the crystal structure of the D3R-eticlopride complex, etherification 
Figure 2. Molecular formulas of test compounds. Caged ligands and control agents based on the structure of 
the selective D2/D3 receptor antagonists eticlopride and dechloroeticlopride. 
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of the phenol function with a bulky benzyl group is suitable to diminish binding affinity. Similar binding profiles 
were expected for the structurally related caged ligands 1 and 2. However, radioligand binding studies indicated 
two-digit nanomolar binding affinity at D2R and D3R. Re-analysis of the samples revealed traces of free eticlo-
pride originated by degradation of the caged ligands explaining the unexpected displacement of radioligand. 
Investigating the dechloro analogs, we found that dechloroeticlopride showed excellent binding affinities towards 
the dopamine receptor subtypes D2R and D3R (Ki = 1.2–2.4 nM), which are comparable to those of eticlopride. In 
agreement with the structure-based receptor model, the caged dechloroeticloprides 4 (MG307) and 5 as well as 
their photostable benzyl analog 6 exhibit weak binding towards the D2- and D3-receptor subtypes (140–1300 nM) 
(Fig. 4A, Supplementary Table 1).
To investigate the functional properties of the caged and uncaged ligands, an IP accumulation assay with D2S 
receptors was performed, indicating that dechloroeticlopride acts as a specific antagonist / inverse agonist. For the 
caged ligands 4 (MG307), 5 and 6 inverse agonist properties were observed as well, but potency was low (Fig. 4B, 
Supplementary Table 3). The caged compounds were able to dose-dependently inhibit the activating effect of 
10 nM quinpirole with IC50 values between 850 and 5500 nM, while dechloroeticlopride clearly inhibited the 
effect of quinpirole at low dose (IC50 = 9.6 nM). Hence, the caged derivatives required much higher concentration, 
when compared to the uncaged analog (Fig. 4C, Supplementary Table 3).
To determine the photolytic uncaging effect onto dopamine receptor promoted signalling, we time- 
dependently measured the change of IP accumulation of D2SR-expressing cells in the presence of 50 nM caged 
compound and 10 nM of the dopamine receptor agonist quinpirole upon illumination with λ = 365 nm. In 
this experimental setting, rapid release of the inverse agonist dechloroeticlopride by photolysis should signif-
icantly attenuate the effect of quinpirole. Actually, we observed an onset of a strong inverse agonist effect on 
quinpirole-induced IP accumulation after irradiation of the nitrobenzyl-caged compound 4 (MG307). Similar 
behavior was observed for the dimethoxynitrobenzyl-caged agent 5. Whereas the caged-compounds did not 
inhibit the activity of quinpirole, irradiation triggered liberation of dechloroeticlopride leading to a blockade 
of receptor signalling. After 2 seconds of irradiation at 365 nm, the agonist effect of quinpirole was diminished 
to less than 30% and no activity could be observed after 10 and 20 seconds for 4 (MG307) and 5, respectively. 
Time-dependent uncaging revealed a more potent inhibition profile for the nitrobenzyl derivative 4 (MG307) 
Figure 3. Photochemical properties of test compounds. (A) UV absorption spectra of eticlopride and its 
photolabile derivatives 1 and 2. (B) UV absorption spectra of dechloroeticlopride and its photolabile derivatives 
4 (MG307) and 5. (C,D) Photolysis of test caged ligands 4 and 5 in aqueous buffer solution at λ = 365 nm. Both 
compounds show fast conversion to dechloroeticlopride within a few seconds.
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compared to the dimethoxynitrobenzyl analog 5, when it showed an inverse agonist effect similar to dechloro-
eticlopride after 10 sec (Fig. 4D). For the photostable reference agent 6, no significant effect upon IP accumula-
tion could be observed both before and after illumination for 20 seconds. To complement uncaging of the test 
compounds by irradiation of the test compounds before addition to receptor by a biologically more significant 
experiment, we investigated whether uncaging can also be accomplished directly in the cellular system. Hence, in 
an IP accumulation assay we irradiated microplates containing cells, buffer and 4 (MG307) or 5 for 10 or 20 sec 
and determined the inhibition of quinpirole-promoted signalling. In fact, quinpirole-promoted IP accumulation 
was substantially attenuated after irradiation for 10 or 20 sec. Employing the nitrobenzyl derivative 4 (MG307), 
the remaining D2S promoted signalling was very low ( < 5%) while the use of compound 5 showed a remaining IP 
accummulation of about 35%, after 10 and 20 seconds (Fig. 4E). The results revealed excellent decaging properties 
of the dechloroeticlopride derivative 4 (MG307). The caged ligand 4 (MG307) appears to be superior for use in 
a cellular test systems, compared to its analog 5. In control experiments, IP accumulation was not changed when 
Figure 4. Biological characterization of dechloroeticlopride and the protected derivatives 4 (MG307), 5, and 6.  
(A) Radioligand displacement curves for dechloroeticlopride and 4–6 at D2S and D3 show a more than 100-
fold difference in affinity indicating a high binding selectivity of the uncaged dechloroeticlopride over the 
caged ligands 4 (MG307), 5 and the control agent 6. Mean curves ± SEM of 4–9 individual curves each done in 
triplicates. (B–D) IP accumulation assay for measuring the inhibitory effect of dechloroeticlopride and 4–6 at 
D2S co-transfected with the hybrid G-protein Gαqi. (B) Inverse agonist effects of the test compounds relative to 
quinpirole. Mean curves from 3–4 experiments each done in duplicate. (C) Inhibition of quinpirole at 10 nM 
(EC80 concentration) shows pronounced selectivity of dechloroeticlopride over 4–6 (Mean curves from 4–6 
experiments done in duplicate). (D) Photoactivation of 4 (MG307) and 5 at 50 nM by irradiation at 365 nm 
shows time-dependent release and a subsequent inhibitory effect at D2SR of the antagonist/ inverse agonist 
dechloroeticlopride. While 4 (MG307) (green bars) is completely released after 10 sec, the uncaging of 5 (red 
bars) needs 20 sec. Irradiation at 365 nm for 20 sec does not affect dechloroeticlopride (black) or the control 
agent 6 (brown). Mean bars ± SEM derived from 3–11 individual experiments each done in quintuplicates. 
Irradiation with a solution of test compound before addition to the cellular test system. (E) Control of 
photoactivation by irradiation of 4 (MG307) and 5 in a cellular test system with D2SR. After irradiation for 10 or 
20 sec, quinpirole promoted IP accumulation was substantially attenuated. Means ± SEM from 6 experiments in 
quintuplicates.
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exposing D2R expressing cells to light (λ = 365 nm, 20 seconds) in presence of quinpirole alone, whereas dechlo-
roeticlopride attenuated signalling (Fig. 4D).
Discussion
Based on the crystal structure of the dopamine D3 receptor in complex with the pharmacological agent eti-
clopride37, we have developed the caged antagonists 4 (MG 307) and 5 subtype selectively targeting dopamine 
D2 and D3 receptors. Caging eticlopride with nitrobenzyl- and dimethoxynitrobenzyl groups yielded 1 and 2, 
compounds with unfavourable photochemical properties and decomposition even in the dark. Inspired by the 
observation that dechloroeticlopride was detected as a photostable degradation product, we synthesized caged 
compounds based on the dechloroeticlopride pharmacophore. Dechloroeticlopride turned out to be a selective 
D2/D3 receptor antagonist38 with excellent receptor binding properties and photostability towards LED light with 
a peak wavelength of λp = 365 nm and a spectrum half width of Δλ = 9 nm. Caging of this ligand with NB- and 
DMNB-groups led to compounds 4 (MG307) and 5. Both derivatives showed improved stability and photochem-
ical properties. The active ligand dechloroeticlopride was liberated in clean uncaging reactions with high relative 
yield, upon illumination of 4 (MG307) and 5.
Biological investigations showed that O-alkylation of the phenolic position of dechloroeticlopride caused 
a drastic decrease of receptor binding affinity for the caged compounds 4 (MG307) and 5. We examined the 
functional effects of photolytic uncaging employing an IP accumulation assay. Whereas the caged benzamides 
4 (MG307) and 5 were not able to attenuate the activation of D2 expressing cells in the presence of Gαqi and 
the dopamine receptor agonist quinpirole, the release of uncaged dechloroeticlopride upon illumination with 
λ = 365 nm induced blockade of D2 receptor-promoted signalling. Thus, the eticlopride derivatives 4 and 5 can 
serve as valuable caged ligands for light-controlled blocking of D2/D3 receptors with high precision via the photol-
ytic release of dechloroeticlopride. Photoactivation by irradiation of 4 (MG307) in a cellular test system for 10 or 
20 sec showed that quinpirole promoted IP accumulation was almost completely attenuated suggesting excellent 
decaging properties of the dechloroeticlopride derivative 4 (MG307).
The research area of photopharmacology using light as a regulator of the effect of bioactive compounds will 
be of growing importance to better understand bimolecular signalling and regulation processes. The rapid spa-
tiotemporal control by use of ligands of type 4 (MG307) upon photo-uncaging may provide valuable insights 
into kinetics of association, dissociation as well as D2/D3 receptor-induced dopaminergic signalling. Until very 
recently, in vivo photopharmacology has been a significant challenge because delivery of UV light to deep tissue 
infusion is technically demanding. However, new wireless devices being able to co-deliver light and drug or prod-
rug simultaneously will serve as powerful technologies for seminal in vivo investigations with caged ligands such 
as compound 4 (MG307).
Methods
chemical synthesis. (S)-3-Ethyl-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-hydroxy-6-methoxybenzamide 
(dechloroeticlopride). A solution of 3-ethyl-2-hydroxy-6-methoxy benzoic acid 9 (64 mg, 0.33 mmol) in CH2Cl2 
(4 ml) was cooled to 0 °C and HOBt (48 mg, 0.36 mmol) and EDC · HCl (69 mg, 0.36 mmol) were added38. After 
stirring at 0 °C for 1 h and at r. t. for 30 min, (S)-(−)-2-aminomethyl-1-ethylpyrrolidine (50 µl, 0.36 mmol) was 
added and the mixture was stirred for 1 h at r. t. The reaction mixture was concentrated in vacuo and taken up in 
MeOH (5 ml). 1 M NaOH (2.5 ml) was added to the solution and the mixture was stirred at 40 °C for 1 h. After 
diluting with a saturated aqueous solution of NaHCO3, the mixture was extracted with CH2Cl2. Drying of the 
combined organic layers (MgSO4) and removal of the solvent under reduced pressure yielded a crude product 
which was purified by flash column chromatography (CH2Cl2/methanol 50: 1 + 0.2% aq. NH3) to yield dechloro-
eticlopride as a colourless oil (73 mg, 73%). IR: 3341, 2967, 2935, 2873, 2842, 2800, 1633, 1608, 1591, 1530, 1450, 
1431, 1292, 1250, 1095, 899, 805 cm−1. 1H-NMR (CDCl3, 600 MHz) δ (ppm): 4.38 (s,br), 1 H), 9.03–8.86 (m,br), 
1 H), 7.14 (d, J = 8.4 Hz, 1 H), 6.33 (d, J = 8.4 Hz, 1 H), 3.89 (s, 3 H), 3.70 (ddd, J = 13.7, 7.1, 2.7 Hz, 1 H), 3.34–3.25 
(m, 1 H), 3.25–3.17 (m, 1 H), 2.85 (dq, J = 14.7, 7.3 Hz, 1 H), 2.70–2.56 (m, 3 H), 2.33–2.16 (m, 2 H), 1.96–1.81 (m, 
1 H), 1.77–1.55 (m, 4 H), 1.19 (t, J = 7.5 Hz, 3 H), 1.13 (dd, J = 7.2 Hz, 3 H). 13C-NMR (CDCl3, 150 MHz) δ (ppm): 
170.6, 162.1, 156.9, 131.8, 126.0, 103.5, 100.0 62.0, 55.8, 53.6, 47.8, 40.7, 28.5, 22.9, 22.5, 14.2, 13.9. α[ ]D
22 = − 48.7° 
(c = 0.36, methanol). HRMS: [M + H]+ calcd. 307.2016; found 307.2016. HPLC: system 1, tR = 16.1 min, 
purity > 99%; system 2, tR = 12.8 min, purity > 99%.
(S)-3-Ethyl-N-[(1-ethylpyrrolidin-2-yl)methyl]-6-methoxy-2-[(2-nitrobenzyl)oxy]benzamide (4, MG307). K2CO3 
(14 mg, 98 µmol) is added to a solution of dechloroeticlopride (20 mg, 65 µmol) in acetone (2 ml) and the mixture 
is refluxed for 30 min. After cooling to room temperature a solution of 2-nitrobenzyl bromide (21 mg, 98 µmol) in 
acetone (1.5 ml) are added. After stirring under reflux conditions for 19 h, the reaction mixture is diluted with a 
saturated aqueous solution of NaHCO3 and extracted with CH2Cl2. The combined organic layers are dried with 
MgSO4 and the solvent is removed under reduced pressure to obtain a crude product. Purification of the product 
is achieved by flash column chromatography employing silica gel and a mixture of CH2Cl2, methanol and aqueous 
NH3 as eluent gave 4 as yellow oil (16 mg, 57%) and an amount of unreacted dechloroeticlopride (6.1 mg, 31%). 
IR: 2967, 2932, 2874, 2838, 2804, 1652, 1603, 1525, 1486, 1271, 1256, 1098, 792, 730 cm−1. 1H-NMR (CDCl3, 
400 MHz) δ (ppm): 8.13 (dd, J = 8.2, 1.2 Hz, 1 H), 8.08 (dd, J = 7.9, 1.0 Hz, 1 H), 7.70 (ddd, J = 7.8, 1.3 Hz, 1 H), 
7.50–7.43 (m, 1 H), 7.20 (d, J = 8.6 Hz, 1 H), 6.71 (d, J = 8.6 Hz, 1 H), 6.47–6.20 (m, 1 H), 5.41 (s, 2 H), 3.81 (s, 3 H), 
3.66 (ddd, J = 13.7, 7.7, 2.8 Hz, 1 H), 3.22–3.01 (m, 2 H), 2.85–2.67 (m, 1 H), 2.67–2.47 (m, 3 H), 2.21–2.01 (m, 
2 H), 1.83–1.46 (m, 4 H), 1.19 (t, J = 7.5 Hz, 3 H), 1.05 (dd, J = 6.9 Hz, 3 H). 13C-NMR (CDCl3, 150 MHz) δ (ppm): 
166.2, 155.2, 154.2, 146.6, 134.6, 133.8, 130.2, 129.8, 128.7, 128.0, 124.6, 121.7, 107.3, 72.8, 62.2, 55.8, 53.4, 47.9, 
40.5, 30.9, 27.8, 22.6, 22.2, 15.0, 13.7. [ ]D
22α  = − 42.9° (c = 0.53, methanol). HRMS: [M + H]+ calcd. 442.2336; 
found 442.2328. HPLC: system 1, tR = 17.2 min, purity 98.4%; system 2, tR = 14.3 min, purity 97.6%.
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Photochemistry. For compound characterization, UV/Vis absorption spectra of samples with c = 0.1 mM in 
methanol were measured on an Analytik Jena Specord 200 Plus spectrometer (λ = 210–400 nm). Irradiation 
experiments to trigger photolysis were performed in open HPLC glass vials using a LED (λ = 365 nm, 4.5 V, 0.7 A) 
to irradiate the samples from top. An aqueous buffer solution served as solvent (50 mM Tris, 1 mM EDTA, 50 mM 
MgCl2, 100 µg/ml bacitracin, 5 µg/ml soybean trypsin inhibitor), with initial sample concentrations of 0.1 nM and 
sample volumes of 100 µl. Photolysis was monitored by HPLC as specified before (eluent system 1). Additional 
HPLC-MS analyses were performed on a Thermo Scientific UltiMate 3000 coupled to a Bruker amaZon SL ESI 
ion trap and employing a Kinetex® 2.6 µm C8 column (75 mm × 2.1 mm, 2.6 µm) at a flow rate of 0.3 ml/min (elu-
ent system 3: methanol/0.1% aq. formic acid, 25% methanol to 100% in 6 min, 100% for 2.5 min). Unless specified 
differently, all experiments were performed in triplicate.
Receptor binding experiments. Receptor binding studies were performed as described previously40,41. In short, 
binding data were obtained in radioligand displacement assays employing homogenates from CHO cells stably 
expressing the human dopamine receptor subtypes D2L, D2S42, D343, and D4.444 and the radioligand [3H]spiperone 
(specific activity: 69 Ci/mmol, PerkinElmer, Rodgau, Germany) at final concentrations of 0,2–0,3 nM. Assays 
were performed with membrane preparations in aqueous binding buffer (50 mM Tris, 1 mM EDTA, 50 mM 
MgCl2, 100 µg/ml bacitracin, 5 µg/ml soybean trypsin inhibitor at pH 7.4) with protein concentrations of 3–6 μg 
per well for D2L, 1 µg per well for D2S, 2–4 µg/well for D3, and 4–10 µg/well for D4.4, respectively. Binding proper-
ties were defined for D2L showing a KD value of 0.12 ± 0.038 nM and a Bmax of 1700 ± 150 fmol/mg protein, for 
D2S with a KD = 0.075 ± 0.025 nM and a Bmax = 5800 ± 750 fmol/mg, for D3 with a KD = 0.14 ± 0.039 nM and a 
Bmax = 3600 ± 620 fmol/mg, and for D2S with a KD = 0.21 ± 0.045 nM and a Bmax = 1300 ± 210 fmol/mg, respec-
tively. Membranes were collected on glass fibre mats (GF/B), dried and melted together with solid scintillator 
before counting the trapped radioactivity in a micro plate reader (MicroBeta2, Perkin Elmer). Competition 
binding experiments with the human dopamine D1, D5, serotonin 5-HT1A, 5-HT2A, and the adrenergic α1A, α2A, 
and β2 receptors were performed with homogenates from HEK293T cells transiently transfected with receptor 
cDNA. Binding experiments were done as described above. For D1 and D5 receptor densities (Bmax value), spe-
cific binding affinities (KD value) for the radioligand [³H]SCH23390 (specific activity: 80 Ci/mmol, Biotrend, 
Cologne, Germany) and the amount of protein per well were set as 3000 fmol/mg protein, 0.31 nM, 5 µg/well 
for D1, and 1100 fmol/mg protein, 0.40 nM, 8 µg/well for D5, respectively. For 5-HT1A the KD value was 0.10 nM, 
Bmax = 3000 fmol/mg, protein = 2 µg/well with 0.2 nM of [3H]WAY600135 (spec. act. = 80 Ci/mmol, Biotrend) 
and for 5-HT2A KD = 0.17 nM, Bmax = 1400 fmol/mg, protein = 7 µg/well with 0.3 nM of [3H]ketanserin (spec. 
act. = 47 Ci/mmol, Biotrend), respectively. α1A Receptor binding was done with a KD = 0,095 nM, Bmax = 7500 
fmol/mg, protein = 2 µg/well with 0.2 nM of [3H]prazosin (spec. act. = 84 Ci/mmol, PerkinElmer), α2A binding 
with a KD = 0.29 nM, Bmax = 900 fmol/mg, protein = 10 µg/well with 0.3 nM of [3H]RX801002 (spec. act. = 57 Ci/
mmol, PerkinElmer), and β2 binding with KD = 0.060 nM, Bmax = 4000 fmol/mg, protein = 3 µg/well with 0.3 nM 
of [3H]CGP12177 (spec. act. = 52 Ci/mmol, Biotrend). Unspecific binding for the dopamine receptors were deter-
mined at 10 µM of haloperidol, for the other receptors 10 µM of the unlabeled radioligand was used. Protein 
concentration was established using the method of Lowry45.
Accumulation of inositol mono phosphate (IP) as functional assay for D2S activation. Determination of the acti-
vation of the dopamine D2S receptor was measured applying the IP-One HTRF® assay (Cisbio, Codolet, France) 
according to the manufacturer’s protocol and as described previously46. In brief, HEK-293T cells were grown 
to a confluence of approx. 70% and transiently co-transfected with the cDNA of the human D2S and the hybrid 
G-protein Gαqi (Gαq protein with the last five amino acids at the C-terminus replaced by the corresponding 
sequence of Gαi; gift from The J. David Gladstone Institutes, San Francisco, CA)47 applying the Mirus TransIT-293 
transfection reagent (Peqlab, Erlangen, Germany). After one day cells were detached from the culture dish with 
Versene (Life Technologies, Darmstadt, Germany), seeded into black 384-well plates (10000 cells/well) (Greiner 
Bio-One, Frickenhausen, Germany) and maintained for 24 h at 37 °C. Agonist properties were determined by 
incubating the test compounds (final range of concentration from 1 pM to 10 μM) in duplicates for 90 min at 
37 °C. Antagonist properties were measured by preincubating the cells with test compounds (10 pM to 10 μM) 
and starting activation by adding quinpirole at 10 nM for further 90 min. Incubation was stopped by addition of 
the detection reagents (IP1-d2 conjugate and Anti-IP1cryptate TB conjugate each dissolved in lysis buffer) for 
60 min at room temperature. Time resolved fluorescence resonance energy transfer (HTRF) was measured using 
the Clariostar plate reader (BMG, Ortenberg, Germany).
Illumination experiments. For the investigation of photoactivating properties we determined the inhibitory 
effect of the test compounds on quinpirole stimulated IP accumulation at the D2S receptor. HEK293T cells were 
transiently co-transfected with D2S and Gαqi. Solutions of the test compounds were irradiated at λ = 365 nm using 
the same LED as for the photochemistry experiments (see above) for 2, 5, 10 or 20 sec and the test compound was 
added to the cell system immediately after illumination. After 30 min of preincubation with test compound recep-
tor activation started by adding 10 nM of quinpirole. Accumulation of IP was determined as described above. 
Pure quinpirole effect was set as 100% activation. Basal activity (buffer) was set as 0%. As a control, quinpirole 
was irradiated for 20 sec without observing any difference to the effect of the untreated analog. To test photoacti-
vation directly in the cellular test system, we investigated the inhibitory effect of 4 and 5 on quinpirole mediated 
IP accumulation by direct irradiation of the cellular test system immediately after addition of the caged ligand to 
the cells and subsequently following the protocol described above. All irradiation experiments were carried out 
in the dark or under dim light.
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Data analysis. The competition curves obtained from receptor binding experiments were analyzed by non-
linear regression using the algorithms in PRISM 6.0 (GraphPad Software, San Diego, CA). Data fitting based 
on a sigmoid model provided IC50 values, representing the concentration corresponding to 50% of maximal 
receptor inhibition. IC50 values were transformed to Ki values according to the equation of Cheng and Prusoff48. 
Normalization was performed by defining total binding equal to 100% and the unspecific binding equal to 0%. 
Data analysis of the functional experiments was performed by nonlinear regression using the algorithms for 
log(agonist) vs. response of PRISM 6.0 and normalization of the raw data to basal (0% = buffer) and the maxi-
mum effect of quinpirole (100%).
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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